CME in Minutes: Education in Cardiology & Pulmonology

Please visit answersincme.com/860/103117485-replay3 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Prof. Solange Peters, MD, PhD and David Harpole, MD. In this activity, experts in EGFR-mutated advanced non–small-cell lung cancer (NSCLC) discuss current and emerging strategies for sequencing therapies beyond progression. Upon completion of this activity, participants should be better able to: Evaluate sequencing strategies for patients with advanced EGFR-mutated NSCLC following first-line progression, applying biologic insights and genomic testing to guide optimal therapy selection; and Discuss the role of emerging therapies in advanced EGFR-mutated NSCLC, applying insights from tumor biology to optimize sequential treatment decisions.

Please visit answersincme.com/860/103117485-replay2 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Prof. Solange Peters, MD, PhD; and Benjamin Levy, MD, FASCO. In this activity, experts in EGFR-mutated advanced non–small-cell lung cancer (NSCLC) discuss how tumor biology and genomic reassessment can guide sequencing after first-line progression. Upon completion of this activity, participants should be better able to: Evaluate sequencing strategies for patients with advanced EGFR-mutated NSCLC following first-line progression, applying biologic insights and genomic testing to guide optimal therapy selection; and Discuss the role of emerging therapies in advanced EGFR-mutated NSCLC, applying insights from tumor biology to optimize sequential treatment decisions.

Please visit answersincme.com/860/103117485-replay1 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Prof. Solange Peters, MD, PhD; and Pasi A. Jänne, MD, PhD. In this activity, experts in EGFR-mutated advanced non–small-cell lung cancer (NSCLC) discuss practical strategies for optimizing first-line testing and treatment selection. Upon completion of this series, participants should be better able to: Interpret updated evidence and recommendations regarding first-line testing and treatment selection for patients with advanced EGFR-mutated NSCLC; and Discuss the role of emerging therapies in advanced EGFR-mutated NSCLC, applying insights from tumor biology to optimize sequential treatment decisions.

Please visit answersincme.com/TNH860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Nick H. Kim, MD and Vallerie V. McLaughlin, MD. In this activity, experts in cardiovascular medicine and pulmonology discuss pulmonary arterial hypertension (PAH). Upon completion of this activity, participants should be better able to: Recognize the importance of treatment escalation for appropriate patients with PAH; Design risk-based treatment escalation plans for patients with PAH; Review the clinical impact of guideline-recommended therapies for risk-based treatment escalation in PAH; and Propose practical considerations to enhance outcomes for patients with PAH requiring treatment escalation.

Please visit answersincme.com/860/IME_2025_00012595-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by John V. Heymach, MD, PhD; and Mark Awad, MD, PhD. In this activity, experts in oncology discuss the role of dual and HER2-selective oral tyrosine kinase inhibitors in patients with HER2-mutated non–small-cell lung cancer. Upon completion of this activity, participants should be better able to: Specify how TKIs may address unmet therapeutic needs for diverse patient populations with HER2-mutated NSCLC; Interpret the clinical evidence for approved oral TKIs for patients with HER2-mutated NSCLC; and Assess which patients may be candidates for approved oral HER2-targeting TKIs in the context of the current standard of care.

Please visit answersincme.com/KAF860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Jill Trinacty, MD, FRCPC, ABOM. In this activity, an expert in endocrinology discusses incretin-based therapies for the management of cardiometabolic risk. Upon completion of this activity, participants should be better able to: Describe the role of incretin-based therapies in cardiovascular risk reduction; Compare cardiovascular outcomes evidence across incretin-based therapies to inform clinical discussions; and Recognize opportunities to identify and address cardiometabolic risk in a multidisciplinary team setting.

Please visit answersincme.com/860/102701687-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Mike Sharma, MD, MSc; and Richard A. Bernstein, MD, PhD. In this activity, experts in stroke discuss post-stroke care and long-term secondary stroke prevention. Upon completion of this activity, participants should be better able to: Discuss evidence-based strategies for secondary stroke prevention, including risk factor modification; Outline the potential role of FXIa inhibitors in closing current long-term management gaps for patients who have had a non-cardioembolic ischemic stroke or TIA; and Design multidisciplinary, long-term secondary stroke treatment plans that effectively leverage all members of the stroke care team, including cardiologists.

Please visit answersincme.com/BGQ860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Marianna Fontana, MD, PhD. In this activity, an expert in cardiology discusses the role of biomarkers and disease-modifying therapies in transthyretin amyloid cardiomyopathy (ATTR-CM). Upon completion of this activity, participants should be better able to: "Differentiate the mechanisms of action and pharmacologic profiles of approved transthyretin (TTR) stabilizers and TTR silencers; Recognize the role of biomarkers and clinical disease features in transthyretin amyloid cardiomyopathy (ATTR-CM) disease assessment and treatment monitoring; and Interpret the latest available data for approved treatments for ATTR-CM.

Please visit answersincme.com/PME860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) discuss strategies for optimizing the detection and management of CRSwNP, with a focus on the role of biologics in patient-centered care. Upon completion of this activity, participants should be better able to: Identify best practices to facilitate the early detection of CRSwNP; Discuss the risk-benefit profiles of approved and emerging biologics for the treatment of CRSwNP; and Identify patient-centered, multidisciplinary strategies to integrate biologics into the treatment algorithm for patients with CRSwNP.

Please visit answersincme.com/XVH860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pulmonology discusses the role of biologic therapy in patients with eosinophilic chronic obstructive pulmonary disease (COPD). Upon completion of this activity, participants should be better able to: Identify patients with unmet therapeutic needs despite guideline-recommended management of chronic obstructive pulmonary disease (COPD); Review the clinical rationale for approved and emerging biologics targeting type 2 inflammation in the treatment of eosinophilic COPD; and Assess strategies to incorporate biologics targeting type 2 inflammation into clinical practice for COPD, as they become available.

Please visit answersincme.com/FBG860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in cardiology and cardiac sonography discuss best practices for using echocardiography for the diagnosis and management of obstructive hypertrophic cardiomyopathy, highlighting how echocardiography may guide treatment decisions with cardiac myosin inhibitors. Upon completion of this activity, participants should be better able to: Review guideline-recommended approaches to diagnose obstructive HCM; Evaluate how cardiac myosin inhibitors fit into the care of patients with obstructive HCM; Specify how echocardiogram may help guide treatment decisions for patients with HCM; and Outline strategies to optimally utilize echocardiography to monitor patients on cardiac myosin inhibitors.

Please visit answersincme.com/GRK860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in medical oncology discusses the role of antibody–drug conjugates (ADCs) in the treatment of HER2-positive metastatic non–small-cell lung cancer (NSCLC). Upon completion of this activity, participants should be better able to: Recognize the difference between HER2 overexpression and HER2 mutation when managing patients with advanced NSCLC; Review the efficacy and safety of HER2-directed antibody–drug conjugates (ADCs) for the treatment of HER2-overexpressing metastatic NSCLC; and Outline clinical approaches to optimize the management of patients with HER2-overexpressing metastatic NSCLC.

Please visit answersincme.com/YWD860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in rhinology discusses the use of biologics for the management of chronic rhinosinusitis with nasal polyps (CRSwNP). Upon completion of this activity, participants should be better able to: Identify key considerations for initiating a biologic therapy in patients with CRSwNP; Discuss the clinical impact of the latest data for novel approved biologics in CRSwNP; and Apply best practice approaches for management of biologics in patients with CRSwNP. This activity is intended for US healthcare professionals only.

Please visit answersincme.com/CZY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in pediatric asthma discuss early intervention with biologic therapy for children with moderate to severe asthma. Upon completion of this activity, participants should be better able to: Identify the role of early intervention with biologics on the long-term lung function of pediatric patients with moderate to severe asthma; Review the clinical impact of biologics approved for the treatment of pediatric patients with moderate to severe asthma on lung function; and Describe evidence-based strategies for optimizing long-term lung function in pediatric patients with moderate to severe asthma. This activity is intended for US healthcare professionals only.

Please visit answersincme.com/MGC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in managing cardiorenal conditions discusses the incorporation of potassium binders into the treatment of hyperkalemia in patients with cardiorenal conditions. Upon completion of this activity, participants should be better able to: Recognize guideline-concordant treatment approaches for hyperkalemia in patients with cardiorenal conditions; Review the clinical profiles of potassium binders approved for the treatment of hyperkalemia in patients with cardiorenal conditions; and Outline management strategies to appropriately incorporate potassium binders into treatment plans for hyperkalemia.